JP2014510064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510064A5 JP2014510064A5 JP2013555631A JP2013555631A JP2014510064A5 JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5 JP 2013555631 A JP2013555631 A JP 2013555631A JP 2013555631 A JP2013555631 A JP 2013555631A JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- formula
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 230000001780 adrenocortical effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446716P | 2011-02-25 | 2011-02-25 | |
| US61/446,716 | 2011-02-25 | ||
| US201161500272P | 2011-06-23 | 2011-06-23 | |
| US61/500,272 | 2011-06-23 | ||
| PCT/US2012/026744 WO2012116362A2 (en) | 2011-02-25 | 2012-02-27 | Chalcone derivatives as nrf2 activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510064A JP2014510064A (ja) | 2014-04-24 |
| JP2014510064A5 true JP2014510064A5 (cg-RX-API-DMAC7.html) | 2015-04-16 |
Family
ID=46721498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555631A Pending JP2014510064A (ja) | 2011-02-25 | 2012-02-27 | Ｎｒｆ２活性剤としてのカルコン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140088052A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2678305A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014510064A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012222074A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2827990A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012116362A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2721003B1 (en) | 2011-06-15 | 2018-01-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2015187934A1 (en) * | 2014-06-06 | 2015-12-10 | Cureveda, Llc | Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use |
| ES2570452B1 (es) * | 2014-10-15 | 2017-04-19 | Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa | Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| WO2016153432A1 (en) * | 2015-03-23 | 2016-09-29 | Nanyang Polytechnic | Drugs from substituted phenyl cinnamyl ketones |
| CA3059192A1 (en) * | 2016-05-26 | 2017-11-30 | The Regents Of The University Of California | Compounds and methods for hematopoietic regeneration |
| AR110590A1 (es) * | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
| CN107056707B (zh) * | 2017-01-23 | 2019-08-23 | 温州医科大学 | 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用 |
| US10947252B2 (en) | 2018-08-20 | 2021-03-16 | Janssen Pharmaceutica Nv | Inhibitors of KEAP1-Nrf2 protein-protein interaction |
| WO2020094767A1 (en) * | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| CN111792990A (zh) * | 2019-04-09 | 2020-10-20 | 中国科学院上海药物研究所 | 一种不饱和酮类化合物、其制备方法和用途 |
| EP4117642A4 (en) * | 2020-03-13 | 2024-05-15 | The Trustees Of Columbia University In The City Of New York | Gpx4 compounds and compositions and methods of treatment using same |
| WO2022148850A1 (en) * | 2021-01-07 | 2022-07-14 | Philip Morris Products S.A. | Compositions comprising anatabine and uses thereof |
| MX2024000806A (es) * | 2021-07-15 | 2024-04-15 | Allspim | Composiciones y métodos para prevenir y/o tratar enfermedades asociadas con la expresión de la interleuquina 23 (il-23). |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| CN115572255A (zh) * | 2022-04-29 | 2023-01-06 | 无锡捷化医药科技有限公司 | 一种查尔酮类化合物的制备方法 |
| CN115433073B (zh) * | 2022-08-15 | 2024-04-19 | 兰州大学 | 一种卡瓦胡椒素b类似物的制备方法及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0740105B2 (ja) * | 1986-03-14 | 1995-05-01 | 清蔵 宮田 | 非線形光学素子 |
| JPH02178249A (ja) * | 1988-12-28 | 1990-07-11 | Mitsubishi Kasei Corp | 光学活性ケトンの製造法 |
| US20030065039A1 (en) * | 1997-06-26 | 2003-04-03 | Statens Serum Institute | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
| PL195212B1 (pl) * | 1997-09-29 | 2007-08-31 | Nektar Therapeutics | Preparat bioaktywny w postaci proszku i sposób jego wytwarzania |
| WO2000018390A1 (fr) * | 1998-09-28 | 2000-04-06 | Hsp Research Institute, Inc. | Inducteurs d'expression de proteine de choc thermique |
| US7247714B2 (en) * | 2001-10-16 | 2007-07-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| KR100830541B1 (ko) * | 2006-08-11 | 2008-05-21 | 충남대학교산학협력단 | 인터루킨-5 저해효과를 갖는 신규 찰콘계 유도체 |
-
2012
- 2012-02-27 JP JP2013555631A patent/JP2014510064A/ja active Pending
- 2012-02-27 EP EP12750204.5A patent/EP2678305A4/en not_active Withdrawn
- 2012-02-27 AU AU2012222074A patent/AU2012222074A1/en not_active Abandoned
- 2012-02-27 CA CA2827990A patent/CA2827990A1/en not_active Abandoned
- 2012-02-27 WO PCT/US2012/026744 patent/WO2012116362A2/en not_active Ceased
- 2012-02-27 US US14/000,816 patent/US20140088052A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510064A5 (cg-RX-API-DMAC7.html) | ||
| JP2004514739A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| JP2016510012A5 (cg-RX-API-DMAC7.html) | ||
| JP2018199684A5 (cg-RX-API-DMAC7.html) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| AR098982A1 (es) | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol | |
| Scichilone et al. | Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD | |
| JP6501774B2 (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2013542940A5 (cg-RX-API-DMAC7.html) | ||
| JP2010132695A5 (cg-RX-API-DMAC7.html) | ||
| AR085120A1 (es) | Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias | |
| SI2393477T1 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| JP2015519356A5 (cg-RX-API-DMAC7.html) | ||
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| US10258634B2 (en) | Ciclesonide for the treatment of airway disease in horses | |
| JP2016510012A (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| JP2016516762A5 (cg-RX-API-DMAC7.html) | ||
| RU2015145135A (ru) | Лечение воспалительных расстройств | |
| JP2014520874A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500731A5 (cg-RX-API-DMAC7.html) | ||
| KR20180118667A (ko) | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 | |
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| JP2019519572A5 (cg-RX-API-DMAC7.html) |